stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Book value per share
Scholar Rock Holding Corporation's book value per share at the end of fiscal 2025 was 2.1×, down 42.0% from 3.7× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 1.9×. Over the past ten years it has ranged from 2.1× (fiscal 2025) to 34.1× (fiscal 2017) — the current reading is the lowest in ten years. Scholar Rock Holding Corporation ranks 284th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 2.1× | (42.04%) |
| FY2024 | 3.7× | 36.64% |
| FY2023 | 2.7× | (38.10%) |
| FY2022 | 4.4× | (6.86%) |
| FY2021 | 4.7× | (44.76%) |
| FY2020 | 8.5× | 106.95% |
| FY2019 | 4.1× | (39.80%) |
| FY2018 | 6.8× | (80.02%) |
| FY2017 | 34.1× | 94.98% |
| FY2016 | 17.5× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 1.9× | (10.40%) |
| Mar 2026 | 2.2× | 1.33% |
| Dec 2025 | 2.1× | (0.65%) |
| Sep 2025 | 2.2× | 4.07% |
| 33 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| MANE Veradermics Incorporated compare | 20.1× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 19.3× |
| CGON CG Oncology, Inc. compare | 11.7× |
| IMVT Immunovant, Inc. compare | 3.6× |
| COGT Cogent Biosciences, Inc. compare | 3.1× |
| SRRK Scholar Rock Holding Corporation | 1.9× |
| ERAS Erasca, Inc. compare | 1.2× |
| KOD Kodiak Sciences Inc. compare | 1.0× |
| PTCT PTC Therapeutics, Inc. compare | −2.3× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Altman Z-score
- The full statement